Evommune于2025年11月6日公开发表,其IPO的定价为每股16美元,并将NYSE作为EVMN进行交易。 Evommune went public on Nov. 6, 2025, pricing its IPO at $16/share and trading on the NYSE as EVMN.

Evommune Inc.的IPO价格为每股16.00美元,提供9.375亿美元的股份,潜在毛收益在开支前为1.5亿美元,包括承保人购买额外股份的选择。 Evommune Inc. priced its IPO at $16.00 per share, offering 9.375 million shares with potential gross proceeds of $150 million before expenses, including an option for underwriters to buy additional shares. 该公司于2025年11月6日以“EVMN”为标志, 开始在纽约证券交易所进行交易。 The company, developing treatments for chronic inflammatory diseases like chronic spontaneous urticaria and atopic dermatitis, began trading on the NYSE on November 6, 2025, under the symbol "EVMN." 这个提议于11月7日结束, 标志着Evommune在生物技术投资促进组织缓慢的一年中向一家公营公司过渡。 The offering, which closed on November 7, marks Evommune’s transition to a public company amid a slow year for biotech IPOs.